AZD0901 (NCT06219941)

Name: AZD0901 trial for Gastric Cancer (NCT06219941)
Uploaded: 2026-10-31T21:30:37.508Z
Duration: 1 min 28 s
Description: AZD0901 trial for Gastric Cancer (NCT06219941). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06219941.

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2: a one-minute explainerNCT062199411 min

AZD0901 trial for Gastric Cancer (NCT06219941). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with advanced CLDN18.2-positive stomach, gastroesophageal-junction, pancreatic or biliary-tract adenocarcinoma. The pancreatic group has no prior treatment for advanced disease.

The idea: infuse AZD0901, an antibody carrying a drug that disrupts cell division to CLDN18.2-bearing cells. Stomach, junction and biliary groups receive it alone; pancreatic groups combine it with chemotherapy. Researchers assess safety and tumor response. Biliary participants need progression after one or two treatment lines; stomach or junction participants can have at most two.

This phase 2 study plans 226 patients. AstraZeneca sponsors seven recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.